Why Esperion Therapeutics Plummeted Nearly 22% Today

·2 min read
Why Esperion Therapeutics Plummeted Nearly 22% Today

Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting